logo

For the Inventor, By the Inventor

Oxfordshire, United Kingdom

Karus Therapeutics Limited


USPTO Granted Patents = 23

% Expired Patents = 56.5



Forward Citations = 162

Loading Chart...
Loading Chart...

16 inventors (with patents filed for the assignee):

goldMedal Stephen Joseph Shuttleworth (22 out of 26 patents)

silverMedal Franck Alexandre Silva (17 out of 20 patents)

bronzeMedal Alexander Richard Liam Cecil (10 out of 14 patents)

4.  Cyrille Davy Tomassi (9 out of 9 patents)

5.  Somhairle MacCormick (6 out of 6 patents)

6.  Thomas James Hill (6 out of 6 patents)

7.  William John Nodes (6 out of 6 patents)

8.  Alexander R L Cecil (3 out of 3 patents)

9.  Andrew David Whale (2 out of 3 patents)

10.  Alexander R Cecil (2 out of 2 patents)

11.  Alexander R Liam Cecil (2 out of 2 patents)

12.  Alice Elizabeth Gatland (2 out of 2 patents)

13.  Daniel John Finnemore (2 out of 2 patents)

14.  Rikki P Alexander (1 out of 1 patent)

15.  Arasu Ganesan (1 out of 3 patents)


23 patents:

1. 11291669 - Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent (2022-04-05),
2. 10870624 - Histone deacetylase inhibitors (2020-12-22),
3. 10668077 - Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent (2020-06-02),
4. 10533003 - Polyheteroarl histone deacetylase inhibitors and their use in therapy (2020-01-14),
5. 10513530 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors (2019-12-24),
6. 10501478 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors (2019-12-10),
7. 10442815 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors (2019-10-15),
8. 10407435 - Diheteroaryl histone deacetylase inhibitors and their use in therapy (2019-09-10),
9. 10377764 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors (2019-08-13),
10. 10150763 - Histone deacetylase inhibitors and their use in therapy (2018-12-11),
11. 10035785 - Phosphoinositide 3-kinase inhibitors (2018-07-31),
12. 9981987 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors (2018-05-29),
13. 9938290 - Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors (2018-04-10),
14. 9862685 - Histone deacetylase inhibitors (2018-01-09),
15. 9676765 - Histone deacetylase inhibitors and their use in therapy (2017-06-13),
Company Overview
Karus Therapeutics Limited is a biopharmaceutical company based in Oxfordshire, UK, focused on developing innovative therapies for cancer and autoimmune diseases. The company specializes in small molecule drug discovery and development, leveraging its expertise in targeted therapies to address unmet medical needs. With a commitment to advancing treatment options, Karus Therapeutics aims to enhance patient outcomes through its research in novel therapeutic modalities and mechanisms of action.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

23 Patents

#8 in Oxfordshire

#772 in United Kingdom

#27,685 in the World

Oxfordshire, GB
Oxfordshire, United Kingdom

Karus Therapeutics Limited

Forward Citations = 162

16 inventors:

goldMedal Stephen Joseph Shuttleworth (22 out of 26 patents)

silverMedal Franck Alexandre Silva (17 out of 20 patents)

bronzeMedal Alexander Richard Liam Cecil (10 out of 14 patents)

4.  Cyrille Davy Tomassi (9 out of 9 patents)

5.  Somhairle MacCormick (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Karus Therapeutics Limited. Retrieved from https://idiyas.com/company/karus-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…